Neuronetics ( (STIM) ) has provided an update.
On February 24, 2025, Neuronetics, Inc.’s Board of Directors approved annual cash incentive compensation awards for key executives, including Stephen Furlong, W. Andrew Macan, and Keith J. Sullivan, with awards amounting to $100,794, $97,313, and $169,260, respectively. These awards, set to be paid on or about March 6, 2025, reflect the company’s commitment to rewarding its leadership, potentially impacting its operational focus and stakeholder confidence.
More about Neuronetics
Neuronetics, Inc. operates in the medical technology industry, focusing on developing non-invasive therapies for psychiatric and neurological disorders. The company is known for its NeuroStar Advanced Therapy system, which is primarily used for treating major depressive disorder.
YTD Price Performance: 185.23%
Average Trading Volume: 1,195,398
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $170.3M
Learn more about STIM stock on TipRanks’ Stock Analysis page.